Search results
Q3 2024 Earnings Forecast for Sarepta Therapeutics, Inc. Issued By Zacks Research (NASDAQ:SRPT)
ETF DAILY NEWS· 7 hours ago(NASDAQ:SRPT – Free Report) – Equities research analysts at Zacks Research upped their Q3 2024 EPS estimates for Sarepta Therapeutics in a research note issued on Monday, ...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 17 hours agoIt's important to note that shares are not forming a chart pattern for investors to watch. On April...
Earnings call: Bio-Techne sees growth in Q3 with strong market positioning By Investing.com
Investing.com· 9 hours agoStrong demand was seen for the ExoDx Prostate test and Comet platform, with the latter expected to...
Gain touts positive Phase I results for Parkinson’s therapy
Clinical Trials Arena via Yahoo Finance· 7 days agoOther Parkinson’s therapies currently in development include Bayer’s gene therapy AB-1005 currently...
Earnings call: Avid Bioservices sees revenue boost, optimistic on growth
Investing.com· 2 days agoDespite this quarterly rise, the company observed a decrease in revenues compared to the same...
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
Benzinga via Yahoo Finance· 6 days agoFriday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate...
Earnings call: Avid Bioservices sees revenue boost, optimistic on growth By Investing.com
Investing.com· 2 days agoDespite this quarterly rise, the company observed a decrease in revenues compared to the same...
Do we need fire sirens? Parents in North Jersey town say it's making their kids miserable
The Bergen Record via Yahoo News· 2 hours ago"Most importantly is for us to ensure that the deactivation of the school siren is enacted as an...
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia - Pfizer (NYSE:PFE)
Benzinga· 6 days agoFriday, the FDA approved Pfizer Inc’s PFE Beqvez (fidanacogene elaparvovec-dzkt) for moderate to...
Earnings call: BioMarin reports solid Q1 growth, plans strategic updates By Investing.com
Investing.com· 7 days agoBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced strong first-quarter financials and strategic...